Agenus (AGEN)
(Delayed Data from NSDQ)
$15.60 USD
+0.21 (1.36%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $15.61 +0.01 (0.06%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
Brokerage Reports
Agenus Inc. [AGEN]
Reports for Purchase
Showing records 161 - 180 ( 259 total )
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
2012 Results; Key Data Catalysts Expected in 2013
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
Enrollment Completed for Phase II Study of HerpV; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
Another Disappointing Quarter; 2013 Guidance Appears Aggressive; Remain on Sidelines
Provider: WEDBUSH SECURITIES INC.
Analyst: ROSE D
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - The State of Cancer Immunotherapy 2.0: Volatility Expected with Busy 2013
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
The State of Cancer Immunotherapy 2.0: Volatility Expected with Busy 2013
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
Bug Off! Second Win for Malaria Phase III Study
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
3Q12 Results; Get Ready for Coming Data Storm; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
HerpV Phase II Gets Rolling as Expected; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
QS-21 Opportunity Continues to Expand with GSK; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
Meetings with Management; Upcoming Stream of Key Catalysts; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
Transferring Coverage and maintaining rating of Market Outperform with $7 price target.
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M